Patent Assignment
Reel/Frame 073715/0375
U.S. Patent Security Agreement
Recorded: 2025-11-25
Pages: 19
Assignor
BAUSCH HEALTH IRELAND LIMITED
Executed: 2025-11-25
Assignee
JPMORGAN CHASE BANK, N.A.
10 S. DEARBORN ST., FLOOR L2, CHICAGO, ILLINOIS, 60603
Covered Properties
(137)
Guanylate Cyclase Receptor Agonists for the Treatment of Tissue Inflammation and Carcinogenesis
Modified Release Formulations of a Bupropion Salt
Alpha Hydroxy Acid Sustained Release Formulation
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Modified Release Formulations of a Bupropion Salt
Bupropion Hydrobromide and Therapeutic Applications
N-[2-Amino-4-(Phenylmethoxy)Phenyl] Amides and Related Compounds as Potassium Channel Modulators
Bupropion Hydrobromide and Therapeutic Applications
Modified-Release Formulations of a Bupropion Salt
Methods and Compositions for Increasing Solubility of Azole Drug Compounds That Are Poorly Soluble in Water
Method for Stabilizing Polypeptides Lacking Methionine
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Derivatives of 4-(N-Azacycloalkyl) Anilides as Potassium Channel Modulators
Naphthyridine Derivatives as Potassium Channel Modulators
Silicone Gel-Based Compositions for Wound Healing and Scar Reduction
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Bupropion Hydrobromide Polymorphs
Bupropion Hydrobromide and Therapeutic Applications
Compositions and Methods for Treating Diseases of the Nail
Patent:
8,039,494 →
Application:
12/803,848 →
Stereoselective Synthesis of Metyrosine
Suspension Containing Micronized Benzoyl Peroxide
Methods and Compositions for Increasing Solubility of Azole Drug Compounds That Are Poorly Soluble in Water
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Compositions and Methods for Treating Diseases of the Nail
Pharmaceutical Formulations Containing Corticosteroids for Topical Administration
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Bupropion Hydrobromide Polymorphs
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Compositions for Increasing Solubility of Azole Drug Compounds That Are Poorly Soluble in Water
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Compositions and Methods for Treating Diseases of the Nail
Process of Preparing Guanylate Cyclase C Agonists
Silicone Gel-Based Compositions for Wound Healing and Scar Reduction
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Agonists Of Guanylate Cyclase And Their Uses
Kinetin/Zeatin Topical Formulation
Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Pharmaceutical Formulations Containing Corticosteroids for Topical Administration
Stereoselective Synthesis of Metyrosine
Modified Release Formulations Of A Bupropion Salt
Compositions and Methods for Treating Diseases of the Nail
Stabilized Efinaconazole Compositions
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Anti-Infective Methods, Compositions, and Devices
Compositions and Methods for Treating Diseases of the Nail
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Ultra-Pure Agonists of Guanylate Cyclase C, Method of Making and Using Same
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Topical Compositions and Methods for Treating Psoriasis
Compositions and Methods for Treating Diseases of the Nail
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Process of Preparing Guanylate Cyclase C Agonisys
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Kinetin/Zeatin Topical Formulation
Stabilized Efinaconazole Compositions
Pharmaceutical Formulations Containing Corticosteroids for Topical Administration
Agonists of Guanylate Cyclase and Their Uses
Compositions and Methods for Treating Diseases of the Nail
Compositions and Methods for Treating Diseases of the Nail
Topical Compositions and Methods for Treating Psoriasis
Formulations of Guanylate Cyclase C Agonists and Methods of Use
Kinetin/Zeatin Topical Formulation
Pharmaceutical Formulations Containing Corticosteroids for Topical Administration
Ultra-Pure Agonists of Guanylate Cyclase C, Method of Making and Using Same
Formulations and Methods for Treating Ulcerative Colitis
Topical Pharmaceutical Compositions for Treating Skin Conditions
Compositions and Methods for Treating Diseases of the Nail
Agonists of Guanylate Cyclase and Their Uses
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Pharmaceutical Formulations Containing Corticosteroids for Topical Administration
Topical Compositions and Methods for Treating Skin Diseases
Multidose Package, Course and Method of Treatment for Delivering Predetermined Multiple Doses of a Pharmaceutical
Anti-Infective Methods, Compositions, and Devices
Topical Pharmaceutical Compositions for Treating Skin Conditions
Polymeric Emulsion Delivery Systems
Stabilized Efinaconazole Formulations
Methods for manufacturing phenoxyethanol
Compositions and Methods for Treating Diseases of the Nail
Topical Compositions and Methods for Treating Acne Vulgaris
Application:
16/822,831 →
Publication:
US 2020/0297684
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Ultra-Pure Agonists of Guanylate Cyclase C, Method of Making and Using Same
Topical Compositions
Anti-Infective Methods, Compositions, and Devices
Stabilized Efinaconazole Compositions as Antifungals
Topical Compositions and Methods for Treating Psoriasis
Topical Compositions and Methods for Treating Psoriasis
Ultra-Pure Agonists of Guanylate Cyclase C, Method of Making and Using Same
Liquid Oral Dosage Formulations of Methylnaltrexone
Application:
17/495,413 →
Publication:
US 2022/0096461
Use of Methylnaltrexone and Rifaximin for Treatment of Increased Gut Permeability or Associated Disorders
Application:
17/529,818 →
Publication:
US 2022/0175764
Compositions and Methods for Treating Diseases of the Nail
Topical Pharmaceutical Compositions for Treating Skin Conditions
Application:
17/714,090 →
Publication:
US 2022/0226271
Topical Compositions and Methods for Treating Skin Diseases
Polymeric Emulsion Delivery Systems
Application:
17/747,938 →
Publication:
US 2023/0000768
Rifaximin Liquid Formulations
Application:
17/763,615 →
Publication:
US 2022/0378758
Topical Compositions Comprising a Macrolide Immunosuppressant
Application:
17/814,474 →
Publication:
US 2022/0362232
Topical Compositions
Methods of Treating Covid-19 with Rifaximin
Application:
17/913,843 →
Publication:
US 2023/0116647
Solid Dispersions of Rifaximin for the Treatment of Overt Hepatic Encephalopathy
Application:
17/913,844 →
Publication:
US 2023/0111568
Methods of Using Solid Dispersions of Rifaximin for the Treatment of Sickle Cell Disease
Application:
17/918,374 →
Publication:
US 2023/0141118
Methods of Reducing Mortality in Subjects Suffering from an Underlying Disease or Condition by Administration of Methylnaltrexone
Application:
17/965,394 →
Publication:
US 2023/0149389
Topical Pharmaceutical Formulations Containing a Low Concentration of Benzoyl Peroxide in Suspension in Water and a Water-Miscible Organic Solvent
Application:
17/969,638 →
Publication:
US 2023/0047106
Pharmaceutical Formulations Containing Corticosteroids for Topical Administration
Pharmaceutical Formulations Containing Corticosteroids for Topical Administration
Topical Compositions and Methods for Treating Psoriasis
Targeted Release Rifaximin Compositions
Application:
18/012,362 →
Publication:
US 2023/0277447
Rifaximin Liquid Formulations for Use in the Treatment of Sickle Cell Disease
Application:
18/034,411 →
Publication:
US 2023/0398102
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Application:
18/186,292 →
Publication:
US 2024/0002440
Ultra-Pure Agonists of Guanylate Cyclase C, Method of Making and Using Same
Amiselimod for Preventing, Treating or Ameliorating Ulcerative Colitis
Application:
18/276,120 →
Publication:
US 2024/0299318
Anti-Infective Methods, Compositions, and Devices
Application:
18/299,664 →
Publication:
US 2023/0293508
Ultra-Pure Agonists of Guanylate Cyclase C, Method of Making and Using Same
Formulations of Guanylate Cyclse C Agonists and Methods of Use
Application:
18/602,930 →
Publication:
US 2025/0049881
Topical Compositions
Topical Compositions
Topical Compositions
Application:
18/901,594 →
Publication:
US 2025/0255895
Ultra-Pure Agonists of Guanylate Cyclase C, Method of Making and Using Same
Application:
18/935,127 →
Publication:
US 2025/0171497
Topical Compositions
Application:
19/278,338 →
Publication:
US 2025/0352569
Vented Tip
Patent:
970,741 →
Application:
29/763,116 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Interest
Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
Security Interest
Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
Release of Security Interest
Mar 6, 2019
From: CRG SERVICING LLC
To: SYNERGY PHARMACEUTICALS INC.
Reel/Frame 048521/0005 →
Security Interest
Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
Intellectual Property Security Agreement
Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
Assignment of Assignor's Interest
Sep 12, 2019
From: DOW PHARMACEUTICAL SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 050358/0528 →
Assignment of Assignor's Interest
Apr 9, 2020
From: SYNERGY PHARMACEUTICALS INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 052358/0134 →
Security Interest
Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
Security Interest
Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
Security Agreement
Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
Security Interest
Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
Security Agreement (First Lien)
Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
Security Agreement (Second Lien)
Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
Security Agreement (Second Lien)
Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
Security Agreement (First Lien)
Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
Security Interest
Feb 13, 2023
From: BAUSCH HEALTH COMPANIES INC.; VALEANT CANADA LP; VALEANT CANADA GP LIMITED; V-BAC HOLDING CORP.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 062670/0260 →
Security Interest
Mar 15, 2023
From: BAUSCH HEALTH COMPANIES INC.; VALEANT CANADA LP; VALEANT CANADA GP LIMITED; V-BAC HOLDING CORP.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 062983/0494 →
Release of Security Interest
Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.
Reel/Frame 070778/0199 →
Assignment of Assignor's Interest
May 1, 2025
From: WERNER, OBEREGGER; ZHOU, FANG; MASSARDO, PIETRO; MAES, PAUL
To: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.
Reel/Frame 071146/0872 →
Merger
May 12, 2025
From: VALEANT INTERNATIONAL BERMUDA
To: VALEANT HOLDINGS IRELAND
Reel/Frame 071088/0061 →
Merger
May 15, 2025
From: VALEANT HOLDINGS IRELAND
To: VALEANT HOLDINGS IRELAND, LUXEMBOURG BRANCH
Reel/Frame 071124/0602 →
Change of Name
May 15, 2025
From: VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 071125/0884 →
Assignment of Assignor's Interest
May 15, 2025
From: VALEANT HOLDINGS IRELAND, LUXEMBOURG BRANCH
To: VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.
Reel/Frame 071130/0894 →
Assignment of Assignor's Interest
May 15, 2025
From: VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.
To: VALEANT PHARMACEUTICALS IRELAND
Reel/Frame 071291/0512 →
Assignment of Assignor's Interest
May 15, 2025
From: VALEANT PHARMACEUTICALS INTERNATIONAL
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 071291/0339 →